Professor Robin Spiller

Professor of Gastroenterology &  Lead Director of the National Institute of Health Research  funded Nottingham Digestive Diseases Biomedical Research Unit at the University of Nottingham, UK.
Editor of Gut an international journal of Gastroenterology and Hepatology from  2003 -2009. Founding Chairman of the Neurogastroenterology and Motility Section of the  British Society of Gastroenterology (BSG). Twice edited the British Society of Gastroenterology ( BSG )Guidelines for the management of IBS and is a member of the Board of the Rome Foundation, an international group which produced the Rome III criteria for the classification of the functional GI diseases. Member of MRC Experimental Medicine and Evaluation Board and National Institute for Health Research  Senior Investigator. 
Main interest is in the pathophysiology of functional GI diseases, particularly focusing on the role of infection and inflammation and alterations in serotonin metabolism in the irritable bowel syndrome. Recent work includes exploiting the use of MRI to image gastrointestinal function in health and disease with particular interest in the role of poorly absorbed carbohydrate  in causing symptoms in IBS. Author/co-author of more than 304 scientific reviews and original publications.


 


Selected recent  Publications

  1. Tooth D, Garsed K, Singh G et al. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea:origin and effect of gut transit. Gut 2013;online

 

  1. Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG, Neal KR, Whorwell PJ, Hall IP, Spiller RC. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha. Gut 2013;62:985-994
  2. Foley S, Garsed K, Singh G, Duroudier NP, Swan C, Hall IP, Zaitoun A, Bennett A, Marsden C, Holmes G, Walls A, Spiller RC. Impaired Uptake of Serotonin by Platelets from Patients with Irritable Bowel Syndrome Correlates with Duodenal Immune Activation. Gastroenterology 2011; 140:1434-43
  3. Marciani L, Cox EF, Hoad CL, Pritchard S, Totman JJ, Foley S, et al. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology. 2010 Feb;138(2):469-77, 77 e1. (12.5)
  4. Spiller R. & Garsed K, Postinfectious Irritable Bowel Syndrome. Gastroenterology 2009;136:1979-88.
  5. Humes DJ, Solaymani-Dodaran M, Fleming KM, Simpson J, Spiller RC, West J. A population-based study of perforated diverticular disease incidence and associated mortality. Gastroenterology 2009;136:1198-1205.
  6. Spiller R. Clinical update: irritable bowel syndrome. Lancet 2007;369:1586-1588.
  7. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-1798.
  8. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
  9. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-357.
  10. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003 Dec;125(6):1651-9.
  11. Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins SM, Spiller RC. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:77-84.
  12. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003;124:1662-1671.
  13. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-811.
  14. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J 1997;314:779-782.